Israel - hebreo - Ministry of Health

abbvie biopharmaceuticals ltd, israel - brimonidine tartrate - תמיסה לעין - brimonidine tartrate 0.15 %w/v - brimonidine - brimonidine - alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Israel - hebreo - Ministry of Health

abbvie biopharmaceuticals ltd, israel - brimonidine tartrate; timolol as maleate - תמיסה לעין - timolol as maleate 0.5 %w/v; brimonidine tartrate 0.2 %w/v - brimonidine - brimonidine - combigan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as monohydrate - טבליה - alendronic acid as monohydrate 10 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures).for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. for the treatment to increase bone mass in men with osteoporosis.

Israel - hebreo - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - latanoprost; timolol as maleate - טיפות עיניים - latanoprost 50 mcg/ml; timolol as maleate 5 mg/ml - other antiglaucoma preparations - reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers.

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

Israel - hebreo - Ministry of Health

teva pharmaceutical indust.ltd - alendronic acid as sodium 70 mg - tablets - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

Israel - hebreo - Ministry of Health

teva pharmaceutical industries ltd, israel - alendronic acid as sodium - טבליה - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.